Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11

ABSTRACT: Super Enhancers (SEs) play a key role in castration-resistant prostate cancer (CRPC) drug resistance. By integrating ChIP-seq and RNA-seq analyses, we identified aberrantly activated super enhancers at the ELF3 and JUNB loci driving their transcriptional up-regulation in abiraterone-resistant prostate cancer cells. Mechanistically, ELF3/JUNB complex directly interacted and activated WNT11 to promote drug resistance and neuroendocrine transformation of prostate cancer cells. In vitro and in vivo experiments confirmed that targeting ELF3/JUNB significantly restored abiraterone sensitivity. This study reveals a critical role of the SE-driven ELF3/JUNB-WNT11 axis in CRPC resistance, providing a new potential therapeutic target to overcome abiraterone resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303076 | GEO | 2026/09/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]

Project description:Super Enhancers (SEs) play a key role in castration-resistant prostate cancer (CRPC) drug resistance. By integrating ChIP-seq and RNA-seq analyses, we identified aberrantly activated super enhancers at the ELF3 and JUNB loci driving their transcriptional up-regulation in abiraterone-resistant prostate cancer cells. Mechanistically, ELF3/JUNB complex directly interacted and activated WNT11 to promote drug resistance and neuroendocrine transformation of prostate cancer cells. In vitro and in vivo experiments confirmed that targeting ELF3/JUNB significantly restored abiraterone sensitivity. This study reveals a critical role of the SE-driven ELF3/JUNB-WNT11 axis in CRPC resistance, providing a new potential therapeutic target to overcome abiraterone resistance.

2026-09-03 | GSE303356 | GEO

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11

Project description:Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11

| PRJNA1293943 | ENA

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]

Project description:Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]

| PRJNA1294880 | ENA

Abiraterone resistance in prostate cancer cells

Project description:Castration resistant prostate cancer (CRPC) develops resistance to antiandrogens affecting Androgen Receptor (AR) signaling through a variety of mechanism. Because of this, the efficacy of androgen receptor targeted therapy remains limited for many patients with CRPC. We developed C42B-Abiraterone (Abi) and resistance cells to study changes in transcriptomic profile compared to parental cells.

2023-01-01 | GSE220467 | GEO

Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide

Project description:We report RNA sequencing data on serial biopsies of prostate cancer VCaP xenografts as the tumors pass from androgen-sensitivity (Pre-Cx), to castration resistance (CRPC, castration resistant prostate cancer), onto resistance to dual therapy with abiraterone plus enzalutamide (AER). From comparison of these RNAseq data sets, we were able to determine differentially expressed genes between the AER/CRPC and Pre-Cx states that could mediate resistance to androgen deprivation therapies.

2018-12-26 | GSE109708 | GEO

Abiraterone resistance in prostate cancer cells

Project description:Abiraterone resistance in prostate cancer cells

| PRJNA909815 | ENA

RNA sequencing analysis of VCaP cells resistant to abiraterone

Project description:Here, we analyze gene expression of prostate cancer cell line VCaP (VCaP WT) and VCaP after long time treatment with abiraterone (VCaP AA) in order to investigate possible resistance mechanisms to second-generation antiandrogens.

2024-06-30 | GSE196523 | GEO

Characterization of an abiraterone ultra-responsive phenotype in castration-resistant prostate cancer patient-derived xenografts

Project description:To identify the molecular signature associated with abiraterone acetate (AA) response and mechanisms underlying AA resistance in castration-resistant prostate cancer patient-derived xenografts (PDXs).

2016-12-22 | GSE85672 | GEO

Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer

Project description:Androgen receptor (AR) pathway inhibition remains the cornerstone for first- and second-line prostate cancer therapies. Although AR signaling inhibitors, such as enzalutamide and abiraterone extend survival in recurrent and castration-resistant prostate cancer (CRPC), durable and complete responses are rare. Resistance mechanisms employed by metastatic CRPC include amplification of AR and AR splice variants in AR-positive CRPC (ARPC) and conversion to AR-null phenotypes, such as double-negative prostate cancer (DNPC) and small cell or neuroendocrine prostate cancer (SCNPC). We have shown previously that DNPC can bypass AR-dependence through fibroblast growth factor (FGF) signaling. However, the role of the fibroblast growth factor receptor (FGFR) pathway in other molecular subtypes of CRPC has not been elucidated.

2023-09-19 | GSE228283 | GEO

Metastatic Castrate-Resistant Prostate Cancer Study (MCRPCS)

Project description:<p>We examined genetic resistance to second generation androgen targeting therapies (abiraterone acetate or enzalutamide) by analyzing whole exome sequencing of patient-matched pre-treatment and post-resistance tumors from a series of castrate-resistant prostate cancer (CRPC) patients. Abiraterone resistant tumors harbored alterations in AR and MYC, whereas patients treated with enzalutamide had acquired alterations in the cell cycle pathway. We experimentally confirmed expression of cell-cycle kinases sufficed to drive enzalutamide resistance, which was mitigated through CDK4/6 blockade. These observations link genetic resistance to specific therapeutic agents to inform strategies in genomically selected advanced CRPC.</p>

| phs001447 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data